Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(VRNA-DD)Market-cap $57 M --Cash $51 M --Shares Out 13.17 M --Great Pipeline -- Strong Insider & Institutional Ownership -- Phase 2b readout of the COPD trial is imminent (during this Q) ,positive results could push this extreme low float stock closer or even above $10 . Unsidocvered and brutally undepriced Stock with massive upside Potential here .GL
Market-Cap $57 M Cash $51 M Price $3.90
Shares Out 13.17 M
"We are very pleased that our four-week Phase 2b dose-ranging clinical trial with nebulized ensifentrine is progressing according to plan and that we have completed enrollment of over 400 symptomatic patients with moderate to severe COPD. We anticipate completing this study around the end of 2019."